JNJ

225.59

-0.87%↓

ABT

92.47

+1.38%↑

MDT

82.98

-0.48%↓

115.58

+0.15%↑

VEEV

161.68

+0.52%↑

JNJ

225.59

-0.87%↓

ABT

92.47

+1.38%↑

MDT

82.98

-0.48%↓

115.58

+0.15%↑

VEEV

161.68

+0.52%↑

JNJ

225.59

-0.87%↓

ABT

92.47

+1.38%↑

MDT

82.98

-0.48%↓

115.58

+0.15%↑

VEEV

161.68

+0.52%↑

JNJ

225.59

-0.87%↓

ABT

92.47

+1.38%↑

MDT

82.98

-0.48%↓

115.58

+0.15%↑

VEEV

161.68

+0.52%↑

JNJ

225.59

-0.87%↓

ABT

92.47

+1.38%↑

MDT

82.98

-0.48%↓

115.58

+0.15%↑

VEEV

161.68

+0.52%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Avatud

SektorTervishoid

1.32

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.32

Max

1.37

Põhinäitajad
By Trading Economics
Sissetulek	-124K -32M
Müük	-372K 1.4M
Aktsiakasum	-0.27
Kasumimarginaal	-2,364.792
Töötajad	161
EBITDA	-13M -42M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+50.38% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-13M 162M
Eelmine avamishind	1.32
Eelmine sulgemishind	1.32

Uudiste sentiment

By Acuity

29%

71%

66 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. apr 2026, 21:14 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: Major Central Bank Meetings Due as Middle East Conflict Continues

26. apr 2026, 21:14 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: Major Central Bank -2-

24. apr 2026, 19:19 UTC

Omandamised, ülevõtmised, äriostud

Intertek Group Rejects EQT's Revised Offer

26. apr 2026, 23:48 UTC

Market Talk

Nikkei May Rise After U.S. Tech Gains -- Market Talk

26. apr 2026, 23:44 UTC

Tulu

Sinopharm 1Q Net CNY1.41B Vs. Net CNY1.46B >1099.HK

26. apr 2026, 23:44 UTC

Tulu

Sinopharm 1Q Rev CNY140.77B Vs. CNY141.66B >1099.HK

26. apr 2026, 23:36 UTC

Market Talk

Uudisväärsed sündmused

Gold Falls Amid Dollar's Strength -- Market Talk

26. apr 2026, 23:33 UTC

Market Talk

Uudisväärsed sündmused

Oil Rises Amid Ongoing Middle East Tensions -- Market Talk

26. apr 2026, 05:12 UTC

Tulu

Citic Securities: Results Also Aided by Higher Income from Brokerage, Income Banking Business >6030.HK

26. apr 2026, 05:12 UTC

Tulu

Citic Securities: Increase in Net Interest Income Supported Results >6030.HK

26. apr 2026, 05:12 UTC

Tulu

Citic Securities 1Q Rev CNY23.16B Vs. CNY16.43B >6030.HK

26. apr 2026, 05:12 UTC

Tulu

Citic Securities 1Q Net CNY10.22B Vs. Net CNY6.61B >6030.HK

24. apr 2026, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Scoring the Cook Era -- Barrons.com

24. apr 2026, 20:51 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Financial Services Roundup: Market Talk

24. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24. apr 2026, 20:39 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 20:09 UTC

Tulu

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24. apr 2026, 19:48 UTC

Market Talk

Uudisväärsed sündmused

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24. apr 2026, 19:25 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 19:25 UTC

Omandamised, ülevõtmised, äriostud

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24. apr 2026, 19:22 UTC

Tulu

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24. apr 2026, 19:06 UTC

Tulu

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24. apr 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24. apr 2026, 18:30 UTC

Omandamised, ülevõtmised, äriostud

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24. apr 2026, 18:28 UTC

Omandamised, ülevõtmised, äriostud

Intertek Rejects Revised EQT Offer

24. apr 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24. apr 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24. apr 2026, 17:42 UTC

Tulu

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24. apr 2026, 17:28 UTC

Tulu

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

50.38% tõus

12 kuu keskmine prognoos

Keskmine 2 USD 50.38%

Kõrge 2 USD

Madal 2 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

66 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.